巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Fate Therapeutics

    FATE
    33.820
    1.140
    3.49%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Fate Therapeutics - 延遲價格・最後更新於 12/08 10:00
    最高位
    35.210
    最低位
    32.850
    開市價
    --
    前收市價
    32.680
    成交量(千)
    138.39
    成交額(百萬)
    40.36
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    3,280.55
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    91.900 - 17.100
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Fate Therapeutics
    證券代碼
    FATE.US
    所屬板塊
    Biotechnology
    公司業務
    Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
    發行量
    97000294
    公司總部
    3535 General Atomics Court, Suite 200
    公司網址
    http://www.fatetherapeutics.com
    公司電郵
    info@fatetherapeutics.com
    公司電話
    +1 858 875-1800

    ARK追蹤 | 掃貨小鵬汽車近10萬股,甩賣京東

    美股情報局·
    ARK追蹤 | 掃貨小鵬汽車近10萬股,甩賣京東

    關於

    Fate Therapeutics(FATE.US)所屬的行業板塊為Biotechnology。
    Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
    詳細公司背景可參考: http://www.fatetherapeutics.com